Cardiovascular issues of cox-2 inhibitors and NSAIDs

Australian Family Physician

Volumn 34, Issue 11, 2005, Pages 945-948

  Wong, Melinda ^a   Chowienczyk, Phil ^b   Kirkham, Bruce ^c  

^a ST VINCENT S HOSPITAL   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; LACTONE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SULFONE;

CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL PROTOCOL; HUMAN; HYPERTENSION; KIDNEY FAILURE; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOLS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; HYPERTENSION; LACTONES; RENAL INSUFFICIENCY; RISK ASSESSMENT; SULFONES;

EID: 33644837782     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (35)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
2. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomised controlled trial. Celecoxib Long term Arthritis Safety Study. JAMA 2000;284:1247-55.
3. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
4. Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98:1725-33.
5. Goldstein JL, Kivitz AJ, Verburg KM, Recker DP, Palmer RC, Kent JD. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther 2003;18:125-32.
6. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
7. Wong M, Toh L, Wilson A, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003;48:81-9.
8. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84.
9. White WB, Strand V, Roberts R, Whelton A. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004;11:244-50.
10. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
11. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.
12. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004;44:140-5.
13. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2 specific inhibitors and cardiorenal function: a randomised, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95.
14. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population based cohort study. Lancet 2004;363:1751-6.
15. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case control study. Lancet 2005;365:475-81.
16. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case control analysis. BMJ 2005;330:1366.
17. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
18. Campen DH, Graham D, Cheetham C, et al. Risk of acute cardiac events among patients treated with cyclooxygenase-2 selective and nonselective nonsteroidal anti-inflammatory drugs. Arthritis Rheum 2004;50(9 Suppl):S657/1756.
19. Layton D, Heeley E, Hughes K, Shakir SA. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription event monitoring (PEM) data. Rheumatology (Oxford) 2003;42:1342-53.
20. Layton D, Hughes K, Harris S, Shakir SA. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology (Oxford) 2003;42:1354-64.
21. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
22. Curtis SP, Mukhopadhyay S, Ramey D, Reicin A. Cardiovascular safety summary associated with the etoricoxib development program. Arthritis Rheum 2003;48(Suppl 9):S616.
23. Singh G, Mithal A, Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. Ann Rheum Dis 2005;64(Suppl III):85. Abstract.
24. Fitzgerald GA. Coxibs and Cardiovascular Disease. N Engl J Med 2004;351:1709-11.
25. Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001;21:1-15.
26. Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004;26:70-83.
27. Krum H, Liew D, Aw J, Haas S. Cardiovascular effects of selective cyclooxygenase-2 inhibitors. Expert Rev Cardiovasc Ther 2004;2:265-70.
28. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalises with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999;19:646-55.
29. Widlansky ME, Price DT, Gokce N, et al. Short and long term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003;42:310-5.
30. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-9.
31. Monakier D, Mates M, Klutstein MW, et al. Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest 2004;125:1610-5.
32. Title LM, Giddens K, McInerney MM, McQueen MJ, Nassar BA. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 2003;42:1747-53.
33. Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium dependent vasodilatation. Circulation 2001;104:2879-82.
34. Wong M, Kirkham B, Jiang B, McNeill K, Chowienczyk P. Effects of indometacin and rofecoxib on vascular function in patients with rheumatoid arthritis. Arthritis Rheum 2004;50(9 Suppl):S383/942.
35. Bulut D, Liaghat S, Hanefeld C, Koll R, Miebach T, Mugge A. Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium dependent vasodilatation in patients with essential hypertension. J Hypertens 2003;21:1663-7.